Table 4.
Comparison of clinicopathological parameters between non-SN metastasis positive (group C) and negative (group D) groups
| Parameter | Total | Number of cases (%) | P value | |||
|---|---|---|---|---|---|---|
| Group C | (%) | Group D | (%) | |||
| 56 | 19 | (33.9) | 37 | (66.1) | ||
| Age (years) | ||||||
| Mean ± SD (range) | 61.6 ± 12.0 | (41–83) | 63.6 ± 11.6 | (40–91) | 0.672 | |
| ≥ 45 | 52 | 17 | (32.7) | 35 | (67.3) | 0.598 |
| < 45 | 4 | 2 | (50.0) | 2 | (50.0) | |
| Primary tumor feature | ||||||
| Clinical T factor | ||||||
| cT1 | 32 | 8 | (25.0) | 24 | (75.0) | 0.141 |
| cT2 | 20 | 10 | (50.0) | 10 | (50.0) | |
| cT3 | 4 | 1 | (25.0) | 3 | (75.0) | |
| Pathological tumor size (mm) | ||||||
| Mean ± SD (range) | 46.2 ± 24.0 | (16–90) | 38.6 ± 24.3 | (8–107) | 0.156 | |
| Pathological invasive tumor size (mm) | ||||||
| Mean ± SD (range) | 40.6 ± 23.3 | (11–90) | 26.6 ± 19.1 | (7–87) | 0.0106 | |
| Pathological T factor | ||||||
| pT1 | 19 | 4 | (21.1) | 15 | (78.9) | 0.131 |
| pT2 | 27 | 9 | (33.3) | 18 | (66.7) | |
| pT3 | 10 | 6 | (60.0) | 4 | (40.0) | |
| Estrogen receptor | ||||||
| Positive | 50 | 16 | (32.0) | 34 | (68.0) | 0.397 |
| Negative | 6 | 3 | (50.0) | 3 | (50.0) | |
| Progesterone receptor | ||||||
| Positive | 46 | 14 | (30.4) | 32 | (69.6) | 0.281 |
| Negative | 10 | 5 | (50.0) | 5 | (50.0) | |
| Human epidermal growth factor receptor 2 | ||||||
| Positive | 5 | 1 | (20.0) | 4 | (80.0) | 0.652 |
| Negative | 51 | 18 | (35.3) | 33 | (64.7) | |
| Ki-67 labeling index (%) | ||||||
| Mean ± SD (range) | 24.2 ± 18.7 | (1.1–65.2) | 17.4 ± 13.3 | (0–61.8) | 0.203 | |
| ≥ 14% | 32 | 12 | (37.5) | 20 | (62.5) | 0.515 |
| < 14% | 24 | 7 | (29.2) | 17 | (70.8) | |
| Nuclear grade | ||||||
| 1 | 18 | 5 | (27.8) | 13 | (72.2) | 0.806 |
| 2 | 10 | 4 | (40.0) | 6 | (60.0) | |
| 3 | 28 | 10 | (35.7) | 18 | (64.3) | |
| Lymphatic invasion | ||||||
| Positive | 38 | 14 | (36.8) | 24 | (63.2) | 0.503 |
| Negative | 18 | 5 | (27.8) | 13 | (72.2) | |
| Sentinel node feature | ||||||
| Number of SN metastasis | ||||||
| ≥ 2 | 16 | 7 | (43.7) | 9 | (56.3) | 0.326 |
| < 2 | 40 | 12 | (30.0) | 28 | (70.0) | |
| SN meta size (mm) | ||||||
| Mean ± SD (range) | 8.7 ± 4.2 | (2.3–18.0) | 5.7 ± 3.0 | (2.1–11.0) | 0.0080 | |
| ≥ 6 mm | 28 | 14 | (50.0) | 14 | (50.0) | 0.0111 |
| < 6 mm | 28 | 5 | (17.9) | 23 | (82.1) | |
| SN ratio | ||||||
| ≥ 0.67 | 38 | 17 | (44.7) | 21 | (55.3) | 0.0131 |
| < 0.67 | 18 | 2 | (11.1) | 16 | (88.9) | |
| SUV parameters | ||||||
| SUVmax1 | ||||||
| Mean ± SD (range) | 5.4 ± 3.5 | (1.1–13.9) | 4.4 ± 2.9 | (0.7–12.8) | 0.279 | |
| ≥ 7.6 | 11 | 6 | (54.5) | 5 | (45.5) | 0.107 |
| < 7.6 | 45 | 13 | (28.9) | 32 | (71.1) | |
| SUVmax2 | ||||||
| Mean ± SD (range) | 6.5 ± 4.6 | (0.8–17.6) | 5.3 ± 4.0 | (0.8–18.3) | 0.283 | |
| ≥ 3.0 | 41 | 17 | (41.5) | 24 | (58.5) | 0.0612 |
| < 3.0 | 15 | 2 | (13.3) | 13 | (86.7) | |
| ΔSUVmax% (%) | ||||||
| Mean ± SD (range) | 16.9 ± 15.3 | (− 27.7–45.7) | 13.8 ± 20.6 | (− 36.7–53.6) | 0.382 | |
| ≥ 20.0 | 25 | 12 | (48.0) | 13 | (52.0) | 0.0458 |
| < 20.0 | 31 | 7 | (22.6) | 24 | (77.4) | |
SD standard deviation, SN sentinel node, SN meta size maximum sentinel node metastasis size, SN ratio number of metastasis-positive SNs/number of all resected SNs, SUVmax maximum standardized uptake value, SUVmax1 SUVmax at 60 min, SUVmax2 SUVmax at 120 min, ΔSUVmax% (SUVmax2 − SUVmax1)/SUVmax1 × 100